NASDAQ:XENT - Intersect ENT Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$29.28 +0.50 (+1.74 %)
(As of 01/22/2019 09:28 AM ET)
Previous Close$28.78
Today's Range$28.3850 - $29.39
52-Week Range$25.09 - $42.95
Volume138,380 shs
Average Volume246,207 shs
Market Capitalization$894.66 million
P/E Ratio-52.29
Dividend YieldN/A
Beta0.64
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$96.30 million
Book Value$3.98 per share

Profitability

Net Income$-16,360,000.00

Miscellaneous

Employees327
Market Cap$894.66 million
OptionableOptionable

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT Inc (NASDAQ:XENT) issued its quarterly earnings results on Monday, November, 5th. The medical equipment provider reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.02. The medical equipment provider earned $24.70 million during the quarter, compared to the consensus estimate of $24.09 million. Intersect ENT had a negative net margin of 20.00% and a negative return on equity of 17.62%. The company's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.15) earnings per share. View Intersect ENT's Earnings History.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Intersect ENT.

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT issued an update on its first quarter 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $26-26.5 million, compared to the consensus revenue estimate of $28.36 million.Intersect ENT also updated its FY 2018 guidance to EPS.

What price target have analysts set for XENT?

7 analysts have issued twelve-month price objectives for Intersect ENT's stock. Their predictions range from $28.00 to $48.00. On average, they expect Intersect ENT's stock price to reach $38.6667 in the next year. This suggests a possible upside of 32.1% from the stock's current price. View Analyst Price Targets for Intersect ENT.

What is the consensus analysts' recommendation for Intersect ENT?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intersect ENT.

What are Wall Street analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:
  • 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (1/6/2019)
  • 2. Northland Securities analysts commented, "We had specifically referenced this drug and these Phase-III studies as risks on the horizon for SINUVA in our note dated 10/03/18. The Phase – III data raise many questions in our mind about SINUVA outlook and the competitive landscape. Caution is warranted vis-a-vis SINUVA. Key Points The f/u for the 2-trials was 24-wks, Dupilumab + mometasone furoate (Nasonex) spray 51% reduction in nasal congestion / obstruction severity vs. 15% for the control arm of mometasone furoate spray in SINUS-24 trial. The numbers stood at 57% and 19% for SINUS-52 trial." (10/17/2018)
  • 3. BTIG Research analysts commented, "Following this morning’s early earnings announcement, management discussed the issues underlying the weak report and reduced sales guidance. Most troubling to us was that instead of SINUVA being easily available via the specialty pharmacy channel, many payors are requiring doctors to either use a payor-affiliated specialty pharmacy partner or to use a buy-and-bill approach. This means doctors must pay to acquire SINUVA, then bill for it and hope they are paid back. While XENT mgmt believes this hurdle can be overcome by showing reluctant docs proof of payment and expanding the salesforce, we think it will be more difficult to change the way ENTs operate. We cut our SINUVA sales estimate for 2H and beyond while also dampening modeled growth rates for PROPEL." (8/2/2018)
  • 4. Canaccord Genuity analysts commented, "We remain buyers ahead of trial data coming up in 4Q18 We believe the stock’s pullback presents opportunity ahead of a catalyst-rich period that is coming up in the near to medium-term. Specifically, we await results on long- term safety of rimegepant (acute treatment of migraine) and a Phase 3 trial on the orally-dissolving tablet (ODT) formulation of rimegepant. Given the behavior of the molecule in two Phase 3 trials so far (see here) and a validated mechanism (Allergan also reported positive results for its ubrogepant; see here), we expect these results to support a potential filing of rimegepant in 2019. a more detailed list of BHVN-related catalysts. We also continue to believe that rimegepant could be a meaningful player in the market for the acute treatment of migraine, and we are reiterating our BUY on BHVN." (8/1/2018)

Has Intersect ENT been receiving favorable news coverage?

News articles about XENT stock have been trending very positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intersect ENT earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Are investors shorting Intersect ENT?

Intersect ENT saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,455,562 shares, an increase of 53.6% from the December 14th total of 947,515 shares. Based on an average trading volume of 361,760 shares, the short-interest ratio is currently 4.0 days. Currently, 4.9% of the company's stock are sold short. View Intersect ENT's Current Options Chain.

Who are some of Intersect ENT's key competitors?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:
  • Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 48)
  • Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 60)
  • Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
  • Mr. Richard E. Kaufman, Technical Advisor (Age 56)
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 54)

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Boston Advisors LLC (0.14%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Which major investors are buying Intersect ENT stock?

XENT stock was acquired by a variety of institutional investors in the last quarter, including Boston Advisors LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Intersect ENT.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $29.28.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $894.66 million and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is http://www.intersectent.com.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]


MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  508
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel